ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Account Active
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / LUNG / insiders
SKYA (43) KRMD (41) APYX (21) PYPD (41) ⌘ Pro Terminal β†’

Pulmonx Corporation (LUNG) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$2.58 -14.14% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.51

Pulmonx Corporation (LUNG) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $129.1M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LUNG Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is LUNG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Pulmonx Corporation (NASDAQ: LUNG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.58 (-14.14% 1D, market cap $129.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LUNG ranks #509 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does LUNG compare to SKYA and KRMD in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), LUNG carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -35.0%. By comparison, SKYA (SkyAI Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M) and KRMD (KORU Medical Systems Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $138.1M). Among the 5-stock peer group, LUNG leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LUNG?
β–Ό

Per LUNG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001127537), Pulmonx Corporation generated $90.5M in revenue (+8.0% YoY), -$54.0M in net income, and -$32.8M in free cash flow against $129.3M in total assets and $37.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.51 (-2.74%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (38/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510038
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (3)Whales (15)SEC (8)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.9% Base Target
$3 Bull$2 Base$2 Bear
πŸ“¬ FREE LUNG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for LUNG)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
πŸ” WHY LUNG SCORES 38/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+15/20 pts (39% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime Γ— Technicals: 68% of 52W Range β€’ RSI-14 at 72.4 (OVERBOUGHT (>70))

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
30
Grade E$1.76+3.4% Next Q
Q2 (-2Q)
33
Grade E$1.82+8.8% Next Q
Q3 (-1Q)
35
Grade E$1.98+30.3% Next Q
Current
38
Grade D-$2.58-7.8% Hist 90D Ξ±
Trajectory: E (30) β†’ D- (38)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a LUNG Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While LUNG currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.09) and Max Pain ($2.71) forces dealer call-delta covering toward $3.41.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LUNGβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œLUNG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

LUNG Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LUNG)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LUNG. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LUNG)

  • βœ“Walkthrough of LUNG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
LUNG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +93.98%β–² ASCENDING CHANNEL
2026-11-03O $3.17H $3.17L $2.58C $2.58VOL 2.41M
RES: $3.29SUP: $1.85SMA50: $2.09SMA200: $1.67
$3.40$2.79$2.19$1.59$0.98RES $3.29SUP $1.85$2.582026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LUNG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ LUNG Butterfly Map β†’ + Track LUNG β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +8.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LUNG today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for LUNG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LUNG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LUNG)

Health Care Rank #509 of 1015 βš”οΈ SKYA vs LUNG Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (LUNG vs. SKYA, KRMD, APYX, PYPD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Pulmonx Corporation (LUNG) ranks #509 by composite RQD confidence (38/100, grade D-) and #623 by equity capitalization ($129.1M). Within this direct 5-issuer industry benchmark cohort, LUNG leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. SKYA currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with LUNG at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LUNG ACTIVE
Pulmonx Corporation
D- 38/100 β€” 74.2% -35.0% -14.14% $129.1M Benchmark Subject
SKYA
SkyAI Inc.
D- 43/100 β€” -30.0% -35.0% -1.35% $128.4M /skya-vs-lung β†’
KRMD
KORU Medical Systems Inc.
D- 41/100 β€” 62.3% -28.7% +2.01% $138.1M /krmd-vs-lung β†’
APYX
Apyx Medical Corporation
E 21/100 β€” 62.5% -28.9% 0.00% $109.5M /apyx-vs-lung β†’
PYPD
PolyPid Ltd.
D- 41/100 β€” β€” -35.0% +0.56% $109.5M /pypd-vs-lung β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001127537 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulmonx Corporation (LUNG) reported GAAP revenue of $90.5M (+8.0% vs. FY2024 revenue of $83.8M , and +31.8% cumulative change since FY2023) , GAAP net income of -$54.0M, operating cash flow of -$32.4M, and free cash flow of -$32.8M (+0.5% YoY). On the balance sheet, LUNG closed FY2025 with $129.3M in total assets against $37.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $90.5M -$54.0M -$32.4M -$32.8M $129.3M $37.0M
FY2024 (FY) 2024-12-31 $83.8M -$56.4M -$31.5M -$33.0M $162.8M $34.0M
FY2023 (FY) 2023-12-31 $68.7M -$60.8M -$37.6M -$37.6M β€” β€”

3. LUNG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LUNG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Pulmonx Corporation (NASDAQ: LUNG) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.58 (-14.14% 1D, market cap $129.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LUNG ranks #509 in composite RQD confidence.

How does LUNG compare to SKYA and KRMD in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), LUNG carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -35.0%. By comparison, SKYA (SkyAI Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M) and KRMD (KORU Medical Systems Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $138.1M). Among the 5-stock peer group, LUNG leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LUNG?

Per LUNG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001127537), Pulmonx Corporation generated $90.5M in revenue (+8.0% YoY), -$54.0M in net income, and -$32.8M in free cash flow against $129.3M in total assets and $37.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LUNG trading relative to its 50-day, 200-day, and 52-week technical levels?

LUNG last traded at $2.58 (-14.14% on volume of 1,437,287 shares), positioning the stock +23.44% above its 50-day simple moving average ($2.09) and +54.49% above its 200-day simple moving average ($1.67). Across its 52-week range of $1.13 to $3.25, LUNG sits at the 68.4% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±12.5% ($2.26 to $2.90).

Direct Sub-Reports: LUNG RQD Cockpit LUNG 12M Forecast LUNG Earnings & Move LUNG Dividends & DRIP LUNG Insiders & 13F LUNG Whale Options LUNG Profit Sankey LUNG News & Why
ROARABLE RATING BRIEF β€’ RQD 38/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

LUNG β€” Pulmonx Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Pulmonx Corporation (LUNG) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.58 (-14.14% 1D, market capitalization $129.1M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 74.2%, operating margin of -59.3%, and free cash flow yield of -24.15%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 6/9, and Debt/Equity of 0.68x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Pulmonx Corporation is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. The profile identifies the company's market capitalization as $0.1B. The reported gross margin of 74.2% indicates a high gross profit share of revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Pulmonx Corporation (LUNG) reported $90.5M in annual revenue (up from $83.8M in FY2024, +8.0% YoY) and -$54.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($68.7M revenue, -$60.8M net income) through FY2025, LUNG scaled operating cash flow to -$32.4M and free cash flow to -$32.8M, backed by $129.3M in total assets against $37.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 38/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -24.15% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $1.13 – $3.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -59.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” for upstream supplier dependencies, downstream customer concentration, or cross-sector correlations. A prospective investor should note that the absence of mapped links means the source data cannot identify 2nd-order bottlenecks; the sector label (Health Care, Medical/Dental Instruments) is the only contextual classification provided.

  • Key Question #1: Can LUNG sustain or expand its -59.3% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $90.5M and free cash flow of -$32.8M, how will capital allocation balance growth reinvestment against $37.0M in total debt?
  • Key Question #3: How sensitive is LUNG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LUNG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pulmonx Corporation (LUNG) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to LUNG Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LUNG Bull vs. Bear Conversation Board β€” What's Your Call at $2.58?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LUNG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LUNG:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $3.88 (+28.9%)
πŸ“Œ Pinned Debate

Revenue grew from $68.7M to $90.5M over the reported fiscal years while net losses narrowed, and the stock has moved 25.6% with a 52-we

The street is overcomplicating Pulmonx Corporation (LUNG). Revenue grew from $68.7M to $90.5M over the reported fiscal years while net losses narrowed, and the stock has moved 25.6% with a 52-week high of $3.25.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $3.25.

CapAlloc_Nerd πŸ‚ BULL

@MidwestValue Agree on the RQD 38/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.01 and keeping dry powder in case we test $2.80.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.26 (-24.9%)
Spot @ $3.01

Free cash flow was negative in every reported period, ROIC is -35%, and the Altman Z-Score is 0.2, indicating significant financial-dis

Sitting on the sidelines or leaning short LUNG above $3.01. Free cash flow was negative in every reported period, ROIC is -35%, and the Altman Z-Score is 0.2, indicating significant financial-distress risk.. Until Fundamental Cash Engine (3/20) and FCF yield (-24.15%) inflect higher, upside is capped near $3.25.

LIVE TAPE